Pharmacokinetics and safety of combination therapy with lithium and risperidone.
Demling
J H
JH
Huang
M-L
ML
Remmerie
B
B
Mannaert
E
E
Sperling
W
W
D000293:Adolescent; D018692:Antimanic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019540:Area Under Curve; D001714:Bipolar Disorder / Q000188:drug therapy / Q000523:psychology; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D018020:Lithium Compounds / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D008297:Male; D011618:Psychotic Disorders / Q000188:drug therapy / Q000523:psychology; D018967:Risperidone / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy
D018692:Antimanic Agents; D014150:Antipsychotic Agents; D018020:Lithium Compounds; D018967:Risperidone